Is This Blue Chip Dividend Stock a Buy for Growth Investors?

The right companies can help investors improve their personal balance sheets. That is because businesses that reliably grow sales and earnings become more valuable to financial markets with each passing year.

An investor who put $3,000 into (NASDAQ: AZN) five years ago and reinvested dividends would have $6,200 today. The same amount put into the S 500 would be worth only $5,200 with dividends reinvested.

But is the stock still a good fit for a growth-oriented portfolio? Let's examine AstraZeneca's fundamentals and valuation to decide.

Continue reading


Source Fool.com